







Bacterial isolates in Blood stream infections from 1st July 2023 – 30th June 2024

Gram positive pathogens from BSI (Adult + Child) July 2023 - June 2024



Gram negative pathogens from BSI (Adult + Child) July 2023 - June 2024





Antimicrobial Susceptibility profile of *S.aureus* from BSI

Organism	Ampicillin	Cefoxitin	Ciprofloxacin	Clindamycin	Co-Trimoxazole	Erythromycin	Linezolid	Vancomycin
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>S.aureus</i> (n=353)	18.98 % (67/353)	51.27 % (181/353)	31.44 % (111/353)	41.92 % (148/353)	50.99 % (180/353)	28.32 % (100/353)	94.05 % (332/353)	97.16 % (343/353)

Organism	Ciprofloxacin	Clindamycin	Co-Trimoxazole	Erythromycin	Linezolid	Vancomycin
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>MRSA</i> (n=167)	10.77 % (18/167)	22.75 % (38/167)	35.32 % (59/167)	11.37 % (19/167)	92.81 % (155/167)	97.00 % (162/167)
<i>MSSA</i> (n=181)	50.27 % (91/181)	59.11 % (107/181)	65.74 % (119/181)	43.64 % (79/181)	96.68 % (175/181)	97.79 % (177/181)
<i>VRSA</i> (n=4)	25.00 % (1/4)	0 (0/4)	0 (0/4)	0 (0/4)	50.00 % (2/4)	0 (0/4)

Antimicrobial Susceptibility profile of *Enterococcus spp* from BSI

Organism	Amoxy - Clav	Ampicillin	Ciprofloxacin	Erythromycin	Linezolid	Penicillin	Tetracycline	Vancomycin
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>E. faecalis</i> (n=30)	76.66 % (23/30)	50.00 % (15/30)	40.00 % (12/30)	33.33 % (10/30)	100 % (30/30)	46.66 % (14/30)	40.00 % (12/30)	90.00 % (27/30)
<i>E. faecium</i> (n=56)	35.71 % (20/56)	14.28 % (8/56)	14.28 % (8/56)	8.92 % (5/56)	96.42 % (54/56)	12.5 % (7/56)	17.85% (10/56)	73.21 % (41/56)

Antimicrobial Susceptibility profile of *Streptococcus pneumoniae* from BSI

Organism	Chloramphenicol	Co-Trimoxazole	Penicillin	Erythromycin	Linezolid	Vancomycin	Levofloxacin
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>S.pneumoniae</i> (n=1)	0 (0/1)	0 (0/1)	100 % (1/1)	0 (0/1)	100 % (1/1)	100 % (1/1)	0 (0/1)

Antimicrobial Susceptibility profile of *Beta haemolytic Streptococci* from BSI

Organism	Erythromycin	Clindamycin	Penicillin
	S% (N/D)	S% (N/D)	S% (N/D)
<i>Beta haemolytic Streptococci</i> (n=1)	0 (0/1)	0 (0/1)	100 % (1/1)

Antimicrobial Susceptibility profile of *Enterobacteriaceae* from BSI

Organism	Amikacin	Aztreonam	Cefoperazone / Sulbactam	Ceftriaxone	Ciprofloxacin
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>E. coli</i> (n=189)	73.54 % (139/189)	51.85 % (98/189)	68.78 % (130/189)	29.62 % (56/189)	39.68 % (75/189)
<i>Klebsiella</i> (n=108)	45.37 % (49/108)	38.88 % (42/108)	44.44 % (48/108)	21.29 % (23/108)	34.25 % (37/108)

Organism	Co-Trimoxazole	Gentamicin	Meropenem	Piperacillin / Tazobactam	Polymixin B
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>E. coli</i> (n=189)	32.37 % (61/189)	45.5 % (86/189)	73.01 % (138/189)	65.07 % (123/189)	33.33 % (63/189)
<i>Klebsiella</i> (n=108)	32.40 % (35/108)	30.55 % (33/108)	49.07 % (53/108)	40.07 % (44/108)	60.01 % (65/108)

Antimicrobial Susceptibility profile of *Salmonella* from BSI

Organism	Ampicillin	Chloramphenicol	Co-Trimoxazole	Ceftriaxone	Ciprofloxacin
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>Salmonella Typhi</i> (n=2)	0 (0/2)	0 (0/2)	100 % (2/2)	100 % (2/2)	100 % (2/2)

Antimicrobial Susceptibility profile of *Pseudomonas* from BSI

Organism	Aztreonam	Cefoperazone / Sulbactam	Ceftazidime	Ciprofloxacin	Gentamicin	Meropenem	Piperacillin / Tazobactam	Polymixin B
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>Pseudomonas</i> (n=94)	17.02 % (16/94)	70.21 % (66/94)	64.89 % (61/94)	71.27 % (67/94)	46.80 % (44/94)	73.40 % (69/94)	77.65 % (73/94)	93.61 % (88/94)

Antimicrobial Susceptibility profile of *Stenotrophomonas maltophilia* organisms from BSI

Organism	Levofloxacin	Co - Trimoxazole
	S% (N/D)	S% (N/D)
<i>Stenotrophomonas maltophilia</i> (n=2)	0 (0/2)	100 % (2/2)

Antimicrobial Susceptibility profile of *Acinetobacter spp* from BSI

Organism	Co-Trimoxazole	Gentamicin	Meropenem	Piperacillin / Tazobactam	Polymixin B
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>Acinetobacter spp</i> (n=68)	38.23 % (26/68)	17.64 % (12/68)	19.11 % (13/68)	20.58 % (14/68)	77.94 % (53/68)

Organism	Amikacin	Aztreonam	Cefoperazone / Sulbactam	Ceftriaxone	Ciprofloxacin
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>Acinetobacter spp</i> (n=68)	26.47 % (18/68)	42.64 % (29/68)	58.82 % (40/68)	19.11 % (13/68)	22.05 % (15/68)

Antimicrobial Susceptibility profile of *SPICE* organisms from BSI

Organism	Amikacin	Aztreonam	Cefoperazone / Sulbactam	Ceftriaxone	Ciprofloxacin
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>Serratia spp</i> (n=11)	54.54 % (6/11)	27.27 % (3/11)	72.72 % (8/11)	18.18 % (2/11)	81.81 % (9/11)
<i>Morganella</i> (n=2)	100 % (2/2)	50.00 % (1/2)	100 % (2/2)	100 % (2/2)	100 % (2/2)
<i>Providencia spp</i> (n=2)	100 % (2/2)	50.00 % (1/2)	50.00 % (1/2)	50.00 % (1/2)	100 % (2/2)
<i>P.mirabilis</i> (n=9)	44.4 % (4/9)	77.77 % (7/9)	88.88 % (8/9)	33.33 % (3/9)	55.55 % (5/9)
<i>Citrobacter spp</i> (n=1)	100 % (1/1)	100 % (1/1)	100 % (1/1)	100 % (1/1)	100 % (1/1)
<i>Enterobacter spp</i> (n=3)	33.3 % (1/3)	33.3 % (1/3)	33.3 % (1/3)	33.3 % (1/3)	33.3 % (1/3)

Organism	Co-Trimoxazole	Gentamicin	Meropenem	Piperacillin / Tazobactam	Polymixin B
	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)	S% (N/D)
<i>Serratia spp</i> (n=189)	0 (0/11)	0 (0/11)	81.81 % (9/11)	90.90 % (10/11)	9.09 % (1/11)
<i>Morganella</i> (n=2)	100 % (2/2)	100 % (2/2)	100 % (2/2)	100 % (2/2)	0 (0/2)
<i>Providencia spp</i> (n=2)	100 % (2/2)	100 % (2/2)	100 % (2/2)	50.00 % (1/2)	0 (0/2)
<i>P.mirabilis</i> (n=9)	0 (0/9)	55.55 % (5/9)	100 % (9/9)	100 % (9/9)	0 (0/9)
<i>Citrobacter spp</i> (n=1)	0 (0/1)	0 (0/1)	100 % (1/1)	100 % (1/1)	0 (0/1)
<i>Enterobacter spp</i> (n=3)	0 (0/3)	33.3 % (1/3)	33.3 % (1/3)	33.3 % (1/3)	66.6 % (2/3)

